Prandin® (Repaglinide) Tablets

Repaglinide is an oral diabetes medicine that stimulates meal‑time insulin release to help reduce post‑meal blood sugar. It is the generic form of Prandin®, used with nutrition and activity plans in adults with type 2 diabetes. With US delivery from Canada, it can fit cash‑pay budgets, including some without insurance.

What Prandin® Is and How It Works

Repaglinide belongs to the meglitinide class, a group of Insulin Secretagogues that prompt pancreatic beta cells to release insulin when eating begins. Its rapid onset and short duration target postprandial glucose, making it useful for flexible meal schedules. The medicine is often used alone or added to other agents, such as metformin, when additional after‑meal control is needed. For background and dosing fundamentals, see Repaglinide Prandin Uses.

Every CanadianInsulin order is prescription‑checked with your clinic and dispensed by a licensed Canadian pharmacy.

Who Prandin® Is For

Indicated for adults with type 2 diabetes to improve glycemic control, repaglinide is particularly helpful when post‑meal spikes are a concern or when meal timing varies day to day. It is not for type 1 diabetes or diabetic ketoacidosis. The medicine’s short action allows meal‑by‑meal dosing decisions under a clinician’s guidance.

• Appropriate for diagnosed Type 2 Diabetes when lifestyle measures alone do not achieve targets.
• May be used as monotherapy or combined with metformin or other non‑insulin agents.
• Avoid in known hypersensitivity to repaglinide or formulation components.
• Use caution in hepatic impairment; dose adjustments and closer monitoring may be required.
• Not studied for use in pregnancy or pediatric populations; clinicians weigh risks and benefits.

Dosage and Usage

Repaglinide is taken before meals to match food‑related glucose rises. Therapy commonly begins with a low dose given prior to each main meal, with adjustments based on self‑monitored glucose and A1C. Titration is typically performed in small increments at frequent intervals until targets are approached while minimizing hypoglycemia risk. When combined with metformin or other agents, clinicians adjust dosing to avoid low blood sugar. For a practical overview of meal‑timed dosing, see Oral Diabetes Medication.

• Administer shortly before meals; taking it with the first bites is acceptable if needed.
• Skip the dose when a meal is skipped.
• Clinicians may titrate to a per‑meal maximum and set a daily cap, depending on response.
• Frequent glucose checks during dose changes help guide safe adjustments.

Label directions vary by country and brand; the prescribing information should guide exact starting dose and titration.

Strengths and Forms

Repaglinide is available as film‑coated oral tablets in multiple strengths commonly published for this medicine: 0.5 mg, 1 mg, and 2 mg. Availability and manufacturers may vary. Tablet color and imprint can differ by source.

Missed Dose and Timing

Because repaglinide works around meals, timing matters. If a meal is delayed, the dose is delayed. If a meal is skipped, the dose is skipped. If a dose is forgotten and eating has already ended, it is usually best to wait until the next meal to reduce the risk of hypoglycemia. Do not double doses.

Storage and Travel Basics

Store tablets at room temperature in the original, child‑resistant container, away from moisture and excess heat. Keep desiccants in the bottle if provided, and close the cap tightly after each use.

When traveling, carry medicine in a labeled pharmacy container within a carry‑on bag. Bring enough tablets for extra days, along with a written medication list. If crossing time zones, a clinician or pharmacist can help plan dose timing relative to meals in the new schedule.

Benefits

Repaglinide helps address after‑meal hyperglycemia and supports overall A1C reduction when used as directed. Its short action can be suited to irregular mealtimes.

• Targets postprandial glucose excursions
• Can be used alone or with other oral agents
• Short duration offers flexible dosing around meals
• Provides an alternative when metformin alone is insufficient
• Allows meal‑by‑meal decisions under a clinician’s guidance
• Well‑studied option within the meglitinide class

Side Effects and Safety

Common side effects include symptoms of low blood sugar and gastrointestinal discomfort. Most effects are mild and improve with dose adjustments and structured meal timing. For practical tips, see Repaglinide Side Effects and Repaglinide Prandin Side Effects.

• Hypoglycemia (shakiness, sweating, hunger, headache)
• Headache or dizziness
• Nausea, diarrhea, or abdominal discomfort
• Upper respiratory symptoms
• Back or joint pain
• Mild weight gain in some patients

Serious but less common risks include severe hypoglycemia, especially with missed meals, excessive dose, alcohol intake, or interacting drugs. Use caution in hepatic impairment. Any signs of severe low blood sugar, loss of consciousness, or allergic reaction warrant urgent medical attention.

Drug Interactions and Cautions

Repaglinide is metabolized primarily by CYP2C8 (and to a lesser extent CYP3A4). Strong inhibitors can raise exposure and increase hypoglycemia risk; inducers can reduce effect. Beta‑blockers may mask adrenergic symptoms of low blood sugar.

• Contraindicated or not recommended with strong CYP2C8 inhibitors such as gemfibrozil; clopidogrel can also markedly increase repaglinide levels.
• Use caution with CYP3A4 inhibitors (e.g., clarithromycin, azole antifungals) and inducers (e.g., rifampin); glucose monitoring and dose adjustments may be needed.
• Other glucose‑lowering agents, including insulin and sulfonylureas, increase hypoglycemia risk when combined.
• Alcohol can potentiate hypoglycemia.
• Illness, reduced food intake, or strenuous activity may necessitate dose reassessment.

Always review a full medication list, including over‑the‑counter products and supplements, with a clinician and pharmacist before starting repaglinide or making changes.

What to Expect Over Time

Post‑meal glucose reductions are typically seen with the first correctly timed doses, reflecting repaglinide’s rapid onset. A1C improvements emerge over weeks with consistent use, matched meal timing, and lifestyle measures. The goal is stable day‑to‑day control with minimal hypoglycemia and acceptable tolerability.

Periodic follow‑up allows dose optimization, assessment of diet and activity patterns, and evaluation of combination therapy if needed.

Compare With Alternatives

Within insulin secretagogues, nateglinide is a related option with a similar meal‑time focus. Outside the class, metformin remains first‑line for many, while SGLT2 inhibitors or GLP‑1–based options may be added when broader benefits are desired. Two common alternatives we carry include Glumetza (metformin extended‑release) and Invokamet (canagliflozin with metformin). Educational reading on repaglinide’s role among options is available under Repaglinide Prandin Uses and broader therapy overviews.

Pricing and Access

Canadian pricing often provides meaningful savings compared with typical US cash costs. Orders are shipped from licensed Canadian pharmacies to eligible US addresses, aligning with our cross‑border model. Expect a streamlined checkout and refill experience, with prompt, express, cold‑chain shipping. Checkout and customer data are protected by encrypted transfer. For current offers, visit our promotions page.

Availability and Substitutions

Availability can vary by strength and manufacturer. If a specific strength is not in stock, a prescriber may recommend a clinically suitable alternative or an equivalent strength using schedule adjustments. Therapeutic alternatives can also be considered when clinically appropriate.

Patient Suitability and Cost‑Saving Tips

• Best suited for adults with type 2 diabetes needing post‑meal control, especially with irregular mealtimes.
• Not appropriate for type 1 diabetes or diabetic ketoacidosis.
• Liver disease, alcohol use, or frequent missed meals increase hypoglycemia risk and warrant careful supervision.
• Combination therapy can reduce dose needs; clinicians may pair repaglinide with metformin.
• Consider multi‑month quantities to decrease per‑fill fees when allowed.
• Set refill reminders and align orders with clinic follow‑ups for uninterrupted supply.

Questions to Ask Your Clinician

• Is repaglinide appropriate given current A1C and meal patterns?
• How should doses be adjusted if meals are irregular or smaller than usual?
• Which signs of hypoglycemia warrant an immediate response plan?
• Are any current medicines likely to interact, such as gemfibrozil or clopidogrel?
• Would adding metformin or changing to another class improve outcomes?
• What glucose targets should guide future titration?
• How often should labs and follow‑ups occur with this therapy?
• What steps help manage dosing during illness or travel?

Authoritative Sources

• DailyMed Repaglinide
• MedlinePlus Repaglinide
• FDA Label Repaglinide

Ready to get started? Submit your prescription and place an order for US delivery from Canada with prompt, express, cold‑chain shipping.

Disclaimer: This information is educational and not a substitute for professional medical advice. Always follow the prescribing information and clinician guidance for individualized care.